HIV / AIDS

Latest News

Gilead Expands Global Access to Lenacapavir With New HIV Prevention Partnership
Gilead Expands Global Access to Lenacapavir With New HIV Prevention Partnership

July 10th 2025

Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.

FDA Accepts New Drug Application for Merck’s HIV Treatment, Doravirine/Islatravir
FDA Accepts New Drug Application for Merck’s HIV Treatment, Doravirine/Islatravir

July 10th 2025

PREPARE Trial: Over Half of Middle-Aged Adults With HIV Experience Physical Function Decline
PREPARE Trial: Over Half of Middle-Aged Adults With HIV Experience Physical Function Decline

July 7th 2025

Supreme Court Affirms ACA Preventive Care Mandate in Kennedy v Braidwood
Supreme Court Affirms ACA Preventive Care Mandate in Kennedy v Braidwood

June 27th 2025

 FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention

June 18th 2025

© 2025 MJH Life Sciences

All rights reserved.